NYSE:PFEPfizer Stock Price, Forecast & News

Pfizer's stock was trading at $32.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PFE shares have increased by 10.0% and is now trading at $35.39. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Pfizer.

Pfizer is scheduled to release its next quarterly earnings announcement on Tuesday, April 28th 2020. View our earnings forecast for Pfizer.

Pfizer will be holding an earnings conference call on Tuesday, April 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Pfizer Inc. (NYSE:PFE) posted its earnings results on Tuesday, January, 28th. The biopharmaceutical company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.57 by $0.02. The biopharmaceutical company earned $12.69 billion during the quarter, compared to the consensus estimate of $12.73 billion. Pfizer had a return on equity of 27.01% and a net margin of 31.44%. The company's revenue for the quarter was down 9.2% on a year-over-year basis. During the same quarter last year, the company earned $0.64 earnings per share. View Pfizer's earnings history.

Pfizer announced a quarterly dividend on Monday, December 16th. Stockholders of record on Friday, January 31st will be paid a dividend of $0.38 per share on Friday, March 6th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.29%. The ex-dividend date is Thursday, January 30th. This is an increase from Pfizer's previous quarterly dividend of $0.36. View Pfizer's dividend history.

Pfizer declared that its board has authorized a stock buyback program on Friday, December 14th 2018, which allows the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to buy up to 3.8% of its stock through open market purchases. Stock buyback programs are typically a sign that the company's leadership believes its stock is undervalued.

Pfizer issued an update on its FY20 earnings guidance on Tuesday, January, 28th. The company provided EPS guidance of $2.82-$2.92 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.72. The company issued revenue guidance of $48.5-$50.5 billion, compared to the consensus revenue estimate of $47.44 billion.

12 brokers have issued 1-year price targets for Pfizer's stock. Their forecasts range from $36.00 to $53.00. On average, they expect Pfizer's stock price to reach $41.30 in the next year. This suggests a possible upside of 16.7% from the stock's current price. View analysts' price targets for Pfizer.

Press coverage about PFE stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pfizer earned a news impact score of -3.3 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutPfizer.

Pfizer saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 59,077,400 shares, an increase of 10.1% from the February 27th total of 53,670,000 shares. Based on an average daily trading volume, of 25,250,000 shares, the days-to-cover ratio is currently 2.3 days. Currently, 1.1% of the company's stock are short sold. View Pfizer's Current Options Chain.

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Verizon Communications (VZ), Intel (INTC), General Electric (GE), Bank of America (BAC), AbbVie (ABBV), Walt Disney (DIS) and Exxon Mobil (XOM).

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Pfizer's stock is owned by a variety of retail and institutional investors. Top institutional investors include Confluence Investment Management LLC (0.04%), Hexavest Inc. (0.04%), M&G Investment Management Ltd. (0.02%), State of Alaska Department of Revenue (0.02%), Nexus Investment Management Inc. (0.01%) and IFM Investors Pty Ltd (0.01%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman, Scott Gottlieb and W Don Cornwell. View institutional ownership trends for Pfizer.

PFE stock was sold by a variety of institutional investors in the last quarter, including Polaris Greystone Financial Group LLC, M&G Investment Management Ltd., Foundation Resource Management Inc., Grassi Investment Management, M&R Capital Management Inc., Private Trust Co. NA, Verity & Verity LLC, and IFM Investors Pty Ltd. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, and Frank A Damelio. View insider buying and selling activity for Pfizer.

PFE stock was purchased by a variety of institutional investors in the last quarter, including CHURCHILL MANAGEMENT Corp, American National Bank, Hexavest Inc., State of Alaska Department of Revenue, IBM Retirement Fund, Nexus Investment Management Inc., Abner Herrman & Brock LLC, and Park National Corp OH. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc, and Scott Gottlieb. View insider buying and selling activity for Pfizer.

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PFE stock can currently be purchased for approximately $35.39.

Pfizer has a market capitalization of $196.33 billion and generates $51.75 billion in revenue each year. The biopharmaceutical company earns $16.27 billion in net income (profit) each year or $2.95 on an earnings per share basis. Pfizer employs 88,300 workers across the globe. View additional information about Pfizer.

The official website for Pfizer is http://www.pfizer.com/.

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.